Skip to content

Cervical Softening and the Prediction of Preterm Birth

Assessment of Cervical SofTening and the Prediction of Preterm Birth'

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05477381
Acronym
STIPP
Enrollment
390
Registered
2022-07-28
Start date
2022-08-18
Completion date
2024-12-31
Last updated
2023-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Incompetence in Pregnancy as Antepartum Condition, Cervical Incompetence, With Delivery, Diagnosis, Premature Birth, Premature Labor, Preterm Birth, Threatened Preterm Labor

Brief summary

Currently, transvaginal cervical length measurement is used to screen in asymptomatic pregnant women with a history of PTB. In symptomatic women, presenting with threatened PTB cervical length in combination with the fibronectin test is used to identify women at high risk to deliver preterm. However, the predictive capacity of transvaginal cervical length measurement is limited. In pregnant women with a history of PTB, it only identifies a proportion of women who will have recurrent PTB. For symptomatic women, 30-60% of these women admitted to the hospital, do not deliver within seven days, leading to overtreatment of these women. Cervical softening is precursor of cervical shortening, effacement and dilatation and therefore cervical softening is a promising new marker that is based on tissue elasticity. However, the predictive value of cervical softening and the relation with spontaneous PTB still has to be determined. With the newly developed Pregnolia® System cervical softness could be measured on a standardized and safe manner. This study could help to improve care for women with a history of spontaneous PTB.

Detailed description

Preterm birth (PTB) is amongst the leading causes of perinatal and childhood morbidity and mortality. Therefore, accurate identification of pregnant women at high risk of PTB is important. Identifying these women, enables obstetric healthcare professionals to apply interventions to postpone delivery and/or to prevent PTB to improve perinatal and childhood outcomes. Currently, transvaginal cervical length measurement is used to screen asymptomatic pregnant women with a history of PTB to identify women requiring a cerclage. In symptomatic women, presenting with threatened (PTB), cervical length in combination with the fetal fibronectin(fFN) test is used to identify women at high risk to deliver within 7 days of presentation. However, the predictive capacity of transvaginal cervical length measurement is limited. In pregnant women with a history of PTB, it only identifies a proportion of women who will have recurrent PTB. For symptomatic women, 30-60% of these women admitted to the hospital, do not deliver within seven days, leading to overtreatment of these women. Since cervical softening is a precursor of cervical shortening, effacement and dilatation, cervical softening is a promising new marker that is based on tissue elasticity. It can be measured with the CE-marked Pregnolia® System for accurate characterization of cervical softening status. It provides a value for tissue elasticity on a continuous scale. A previous study has shown that softening of the cervix can be detected before shortening of the cervix. The Pregnolia® System may allow to detect women at risk for PTB earlier compared to traditional transvaginal ultrasound that measures shortening of the cervix, and therefore may prove useful for a more accurate risk assessment of PTB. This current study is a single centre cohort study, where Two cohorts of women will be investigated. 1) Asymptomatic pregnant women with a history of spontaneous PTB before 34 weeks of gestation (Cohort A-STIPP). 2) Symptomatic women presenting with threatened PTB between 24 and 34 weeks (Cohort S-STIPP). Objective: The aim of this study is to evaluate the predictive capacity of cervical softening and risk of PTB.

Interventions

DIAGNOSTIC_TESTMeasurement of cervical stiffness by Pregnolia Device

The Pregnolia® System is designed to provide information about the mechanical properties of the cervical tissue by assessing the CSI (Cervical Stiffness Index) through a probe that will create a weak vacuum to retract tissue. The Pregnolia® System is designed with the purpose to provide an alternative diagnostic marker to identify women at risk of spontaneous PTB. The Pregnolia® System is a CE-marked device developed for quantitative assessment of softening of the uterine cervix. The Pregnolia® System will be applied within its intended use.

Sponsors

Pregnolia AG
CollaboratorINDUSTRY
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 18 years or above. * Ability to understand Dutch or English (both spoken and written). * Ultrasound-based gestational age determined by measurement of crown rump length (CRL) determined between 9 and 11 weeks of gestation. * Singleton and twin pregnancies. Cohort A-STIPP specific: \- Medical history of spontaneous preterm birth before 34 weeks of gestation Cohort S-STIPP specific: * Threatened Preterm birth between 24 and 34 weeks of gestation. * Threatened preterm birth is defined as: * abdominal pain * (Braxton Hicks) contractions * vaginal blood loss.

Exclusion criteria

* Under 18 years of age. * Signs of intrauterine infection. * Obstetric indication for immediate delivery (advanced labor, cord prolapse, abruption, signs of fetal distress). * Confirmed fetal abnormality. * Confirmed preterm rupture of membranes. * Confirmed vasa / placenta praevia. * Severe vaginal bleeding and light bleeding that cannot be stopped. * Signs of imminent labor such as blood loss, regular contractions.

Design outcomes

Primary

MeasureTime frameDescription
Spontaneous Preterm Birth < 34 weeksMaximum time frame up to 28 weeks: from inclusion at 14 weeks of gestational age until delivery, with a maximum of 42 weeks of gestational age.Spontaneous preterm birth before 34 weeks of gestation in the asymptomatic cohort
Delivery within seven days after inclusionFrom inclusion until 7 days laterDelivery within seven days after inclusion in the symptomatic cohort

Secondary

MeasureTime frameDescription
Spontaneous preterm birth <28 weeksFrom inclusion (symptomatic cohort 24-34 weeks, asymptomatic cohort 14 weeks) until delivery with a maximum of 42 weeks of gestational ageSpontaneous preterm birth \<28 weeks of gestational age
Prediction of preterm birth using cervical softening.From inclusion (symptomatic cohort 24-34 weeks, asymptomatic cohort 14 weeks) until delivery with a maximum of 42 weeks of gestational ageDevelopment of a prediction model using cervical softening to predict the risk of preterm birth before 37, 34, 32 and 28 weeks.
Prediction of preterm birth using the combination of cervical softening and transvaginal cervical length measurement.From inclusion (symptomatic cohort 24-34 weeks, asymptomatic cohort 14 weeks) until delivery with a maximum of 42 weeks of gestational ageDevelopment of a prediction model using the combination of cervical softening and transvaginal cervical length measurement to predict the risk of preterm birth before 37, 34, 32 and 28 weeks.
Prediction of preterm birth using the combination of cervical softening, transvaginal cervical length measurement, and fetal fibronectin.From inclusion (symptomatic cohort 24-34 weeks) until delivery with a maximum of 42 weeks of gestational ageDevelopment of a prediction model using the combination of cervical softening, transvaginal cervical length measurement, and fetal fibronectin to predict the risk of preterm birth before 37, 34, 32 and 28 weeks. (only for symptomatic women)
Prediction of latency time using cervical softening.From inclusion (symptomatic cohort 24-34 weeks, asymptomatic cohort 14 weeks) until delivery with a maximum of 42 weeks of gestational ageDevelopment of a prediction model using cervical softening to predict the latency time (interval between inclusion and delivery).
Prediction of latency time using the combination of cervical softening and transvaginal cervical length measurement.From inclusion (symptomatic cohort 24-34 weeks, asymptomatic cohort 14 weeks) until delivery with a maximum of 42 weeks of gestational age.Development of a prediction model using the combination of cervical softening and transvaginal cervical length measurement to predict the latency time (interval between inclusion and delivery).
Prediction of latency time using the combination of cervical softening, transvaginal cervical length measurement, and fetal fibronectinFrom inclusion (symptomatic cohort 24-34 weeks) until delivery with a maximum of 42 weeks of gestational age.Development of a prediction model using the combination of cervical softening, transvaginal cervical length measurement, and fetal fibronectin to predict the latency time. (interval between inclusion and delivery). (only for symptomatic women)
Spontaneous preterm birth <37 weeksFrom inclusion (symptomatic cohort 24-34 weeks, asymptomatic cohort 14 weeks) until delivery with a maximum of 42 weeks of gestational ageSpontaneous preterm birth \<37 weeks of gestational age
Spontaneous preterm birth <34 weeksFrom inclusion (symptomatic cohort 24-34 weeks, asymptomatic cohort 14 weeks) until delivery with a maximum of 42 weeks of gestational ageSpontaneous preterm birth \<34 weeks of gestational age
Spontaneous preterm birth <32 weeksFrom inclusion (symptomatic cohort 24-34 weeks, asymptomatic cohort 14 weeks) until delivery with a maximum of 42 weeks of gestational ageSpontaneous preterm birth \<32 weeks of gestational age

Other

MeasureTime frameDescription
Preterm Prelabour Rupture of membranes at moment of measurementWithin 1 hour after measurementPreterm Prelabour Rupture of membranes at moment of measurement
Irritation and sensitization of mucosal tissueWithin 1 hour after measurementIrritation and sensitization of mucosal tissue as noticed by the researcher performing the measurement
Superficial lacerations or minor tissue abrasionsWithin 1 hour after measurementSuperficial lacerations or minor tissue abrasions
Patient discomfort of Pregnolia measurementIn asymptomatic cohort at 14, 16, 18, 20, 22 and 24 weeks of gestational age, in the symptomatic cohort at moment of inclusionPain during Pregnolia measured on a visual analogue scale (VAS) from no painto worst possible pain
Infections within seven days of measurementFrom inclusion up to 1 weekInfections within seven days of measurement (urinary tract infections, vaginal infections, intra-uterine infections)
Vaginal or Cervical blood loss (directly after measurement)In asymptomatic cohort at 14, 16, 18, 20, 22 and 24 weeks of gestational age, in the symptomatic cohort at moment of inclusionVaginal or Cervical blood loss, noticed directly (= within 30 minutes) after measurement

Countries

Netherlands

Contacts

Primary ContactSofie Breuking, drs
s.h.breuking@amsterdamumc.nl+ 31205669111
Backup ContactFrederik Hermans, PhD, MSc
f.j.hermans@amsterdamumc.nl+31205669111

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 8, 2026